Certified by Founder
Lodge
Congruence Therapeutics
start up
Canada
- Montreal, Quebec
- 07/03/2023
- Series A
- $65,000,000
Congruence Therapeutics is a drug discovery company that is uniquely harnessing the power of innovative fields such as protein dynamics, biophysics, machine learning and computational chemistry. Our ground-breaking discovery engine, Revenir, sees proteins in ways others have been unable to see - in their full dynamic state.
- Industry Biotechnology Research
- Website https://congruencetx.com/
- LinkedIn https://www.linkedin.com/company/congruencetx/people/
Related People
Clarissa DesjardinsFounder
Canada -
Montreal, Quebec,
Experienced biotechnology executive and founder of three successful biotechnology companies. Founded Clementia Pharmaceuticals and led it to Phase 3 human clinical trials for fibrodysplasia ossificans progressiva (FOP), a disease of abnormal new bone formation, until its acquisition by Ipsen for $1.3 billion dollars in 2019.
Parhelia Biosciences | Undisclosed Amount | (Oct 18, 2023)
Cloover | $7,388,000 | (Oct 18, 2023)
Hallmark Health Care Solutions | Undisclosed Amount | (Oct 18, 2023)
Prove | $40,000,000 | (Oct 18, 2023)
Reality Defender | $15,000,000 | (Oct 18, 2023)
Yardstik | $12,000,000 | (Oct 18, 2023)
Nucleus RadioPharma | $56,000,000 | (Oct 18, 2023)
Society Brands | $25,000,000 | (Oct 18, 2023)
Nova Credit | $45,000,000 | (Oct 18, 2023)
Anonybit | $3,000,000 | (Oct 18, 2023)
Zelus Analytics | Undisclosed Amount | (Oct 18, 2023)
Scorability | $11,000,000 | (Oct 18, 2023)